Integer Holdings (ITGR) AI Stock Analysis

• Market Cap: $2.45B
• Dividend Yield: N/A
• Average Volume (3M): 973.63K
• Price to Earnings (P/E): 28.9
• Beta (1Y): 0.55
• Revenue Growth: 7.81%
• EPS Growth: -26.32%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.79
• Shares Outstanding: 35,038,425
• 10 Day Avg. Volume: 453,979
• 30 Day Avg. Volume: 973,625
• PEG Ratio: 1.15
• Price to Book (P/B): 2.75
• Price to Sales (P/S): 2.59
• P/FCF Ratio: 44.71
• Enterprise Value/Market Cap: 1.99
• Enterprise Value/Revenue: 2.66
• Enterprise Value/Gross Profit: 9.85
• Enterprise Value/Ebitda: 13.66
• 1Y Price Target: $91.50
• Price Target Upside: 27.79% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 65 Neutral
• Price Target: $74.00 ▲(3.35% Upside)

Integer Holdings' overall score is driven by strong financial performance and positive corporate events. However, technical indicators suggest bearish momentum, and valuation metrics indicate limited upside potential. Earnings call insights reveal near-term challenges, impacting the overall outlook.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong market position and effective business model, enhancing long-term financial stability.

Share Repurchase Program

The share repurchase program reflects management's confidence in the company's strategy and financial health, potentially boosting shareholder value.

New CEO Appointment

The new CEO's leadership is expected to drive growth and strengthen strategic positioning, enhancing long-term competitive advantage.

Negative Factors

Profitability Pressure

Decreasing profitability and rising leverage could strain financial resources and limit growth opportunities, impacting long-term sustainability.

Reduction in 2025 Outlook

Reduced financial outlook for 2025 indicates potential challenges in meeting growth targets, affecting investor confidence and strategic planning.

Market Exit Impact

Exiting a market segment could reduce revenue streams and limit diversification, impacting the company's growth trajectory and market adaptability.

Integer Holdings Business Overview & Revenue Model

Company Description

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

How the Company Makes Money

Integer Holdings generates revenue through several key streams, primarily from the sale of medical devices and related services. The company's revenue model is centered around its core product offerings, which include implantable devices for cardiac rhythm management, neuromodulation, and orthopedic applications. Integer also earns income from contract manufacturing services, where it partners with other medical device companies to produce specialized products. Significant partnerships with major healthcare providers and OEMs (original equipment manufacturers) contribute to its earnings by securing long-term contracts and fostering innovation. Additionally, Integer's focus on research and development allows it to introduce new technologies and products, further enhancing its market presence and revenue potential.

Integer Holdings Financial Statement Overview

Summary

Integer Holdings shows steady revenue growth and strong cash flow generation, but faces challenges in maintaining profitability margins and managing increased leverage.

Income Statement

Integer Holdings has demonstrated consistent revenue growth, with a TTM increase of 2.02% and a solid gross profit margin of 26.89%. However, the net profit margin has decreased to 4.75% in the TTM, indicating some pressure on profitability. The EBIT and EBITDA margins have also shown a decline, suggesting increased operational costs or other financial pressures.

Balance Sheet

The company's debt-to-equity ratio of 0.75 in the TTM indicates a moderate level of leverage, which is manageable but has increased compared to previous years. The return on equity has decreased to 5.21%, reflecting a decline in profitability relative to shareholder equity. The equity ratio remains stable, suggesting a balanced approach to financing.

Cash Flow

Integer Holdings has shown strong free cash flow growth of 12.38% in the TTM, indicating improved cash generation capabilities. The operating cash flow to net income ratio is nearly 1, suggesting efficient cash conversion. The free cash flow to net income ratio of 0.91 further highlights robust cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.83B	1.72B	1.56B	1.33B	1.22B	1.07B
Gross Profit	494.27M	461.18M	411.52M	346.65M	336.97M	285.71M
EBITDA	356.30M	332.94M	275.71M	221.75M	224.65M	182.99M
Net Income	86.90M	119.90M	90.65M	66.38M	96.81M	77.26M
Balance Sheet
Total Assets	3.40B	3.08B	2.94B	2.79B	2.58B	2.37B
Cash, Cash Equivalents and Short-Term Investments	58.94M	46.54M	23.67M	24.27M	17.89M	49.21M
Total Debt	1.31B	1.10B	1.05B	1.01B	905.81M	777.55M
Total Liabilities	1.65B	1.46B	1.42B	1.38B	1.23B	1.10B
Stockholders Equity	1.75B	1.62B	1.52B	1.42B	1.35B	1.27B
Cash Flow
Free Cash Flow	165.54M	99.60M	60.27M	41.65M	103.20M	129.90M
Operating Cash Flow	203.96M	205.21M	180.21M	116.38M	156.67M	181.34M
Investing Cash Flow	-205.65M	-195.41M	-163.37M	-200.42M	-271.00M	-56.58M
Financing Cash Flow	22.97M	13.32M	-18.01M	92.48M	81.99M	-88.58M

Integer Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 71.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITGR, the sentiment is Neutral. The current price of 71.6 is above the 20-day moving average (MA) of 69.86, below the 50-day MA of 81.17, and below the 200-day MA of 106.61, indicating a neutral trend. The MACD of -2.15 indicates Negative momentum. The RSI at 46.33 is Neutral, neither overbought nor oversold. The STOCH value of 25.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ITGR.

Integer Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TMDX	77 Outperform	$4.67B	55.18	32.48%	―	41.20%	173.53%
INSP	72 Outperform	$3.98B	93.83	6.54%	―	16.81%	34.90%
ITGR	65 Neutral	$2.45B	28.94	5.18%	―	7.81%	-26.32%
LIVN	63 Neutral	$3.46B	―	-17.63%	―	8.97%	-1024.86%
GKOS	61 Neutral	$6.23B	―	-12.19%	―	30.38%	47.64%
ATEC	57 Neutral	$3.19B	―	-540.40%	―	27.11%	17.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Integer Holdings Corporate Events

Integer Holdings Announces $200M Share Repurchase Program

On November 3, 2025, Integer Holdings Corporation’s Board of Directors approved a share repurchase program allowing the company to buy back up to $200 million of its common stock. This initiative, announced on November 4, 2025, reflects the Board’s confidence in the company’s strategy and financial health, intending to use cash on hand and free cash flows for the repurchases. The program’s flexible nature allows management to execute repurchases opportunistically, potentially impacting the company’s stock value and shareholder returns positively.

Integer Holdings Appoints Payman Khales as New CEO

On October 24, 2025, Integer Holdings Corporation announced the completion of its planned leadership transition with Payman Khales assuming the roles of President and CEO, succeeding Joseph Dziedzic. Mr. Khales, who joined Integer in 2018, has been instrumental in driving growth and improving service levels in his previous roles, and his appointment is expected to continue advancing the company’s strategic goals and strengthen its position as a strategic partner in the medical device industry.

Integer Holdings Reports Strong Q3 2025 Sales Growth

Integer Holdings Corporation reported an 8% increase in sales for the third quarter of 2025, with significant growth in cardio and vascular sales driven by new product introductions and acquisitions. Despite a decrease in GAAP operating income, the company achieved a 14% rise in non-GAAP adjusted operating income and a 25% increase in adjusted EPS. Integer anticipates challenges in 2026 but expects a return to above-market growth by 2027, supported by its robust product development pipeline.